GBA2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P02799(GBA2 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The GBA2 antibody targets the enzyme glucosylceramidase beta 2 (GBA2), a membrane-associated protein encoded by the GBA2 gene. Unlike its paralog GBA1. which is a lysosomal enzyme linked to Gaucher disease, GBA2 is a non-lysosomal glucosylceramidase localized to the endoplasmic reticulum and cell membrane. It plays a role in glycolipid metabolism by hydrolyzing glucosylceramide to glucose and ceramide, influencing cellular processes like membrane dynamics and signaling.

GBA2 gained attention due to its association with hereditary spastic paraplegia (HSP) and cerebellar ataxia. Mutations in the GBA2 gene are implicated in neurodegenerative disorders, highlighting its importance in maintaining neuronal health. Research also suggests potential links to other conditions, including multiple sclerosis and cancer, though mechanisms remain under investigation.

Antibodies against GBA2 are critical tools for studying its expression, localization, and function. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding in disease-related research and biomarker discovery. Commercial GBA2 antibodies are typically validated for specificity across human and murine samples, though variability in isoform detection requires careful experimental design.

Current challenges include understanding GBA2's precise physiological roles and reconciling conflicting findings across studies. The development of high-affinity, well-characterized GBA2 antibodies remains essential for advancing translational research in neurology and oncology.